Jesse M. Zaretsky Created 2026-10-20 Updated 2026-11-05
Researcher studying resistance to immune checkpoint blockade. Zaretsky and collaborators investigated acquired resistance to PD-1 blockade in melanoma, connecting changes in tumor cells with loss of therapeutic response.[ref]
Maartje W. Rohaan Created 2026-10-20 Updated 2026-11-05
Researcher in immunotherapy. Rohaan and collaborators compared tumor-infiltrating lymphocyte therapy with ipilimumab in advanced melanoma, directly testing alternative treatment strategies rather than inferring benefit from immune activity alone.[ref]
Melanocytic lesion 2026-11-05
A melanocytic lesion is a localized abnormal growth or proliferation involving melanocytes, the pigment-producing biological cells of the skin. The description identifies the participating cell lineage; it does not by itself mean cancer. A common melanocytic nevus is a noncancerous clustered growth of melanocytes, whereas melanoma is malignant. The National Cancer Institute distinguishes these categories explicitly.[ref]
Common Moles, Dysplastic Nevi, and Risk of Melanoma by the National Cancer Institute. What is a common mole? and Can a common mole turn into melanoma?
A visible pigmented spot and a histological section provide different evidence. Pigment is an optical observation; a melanocytic lesion is a statement about the biological process. Microscopic examination asks how melanocytes are arranged in the sampled tissue and how that pattern relates to surrounding structures. Clinicopathological correlation connects those observations to the particular lesion that was sampled.
The sampling distinction can be made quantitative without inventing a diagnostic rule. In a constructed lesion containing relevant cells, examining a section that contains cells does not automatically inspect all . If a feature is absent from the section, it may be absent from the lesion or located outside the sampled region. Increasing the number of levels or changing the sampled location changes the evidence available, rather than merely changing the name assigned to it.
Classification is also an observer task. A primary study of skin biopsy interpretations included a spectrum from nevi to invasive melanoma and distinguished agreement with a consensus reference from agreement on repeat interpretation.[ref]
Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study by Joann G. Elmore and others. Abstract, five diagnostic classes and observer/reference comparison
This motivates precise statements of the category, sampled material and diagnostic reproducibility. A lineage label alone does not specify benignity, invasiveness or a complete clinical diagnosis. Melanocytic nevus 2026-11-05
A melanocytic nevus is a benign localized growth of melanocytes, commonly called a mole. It belongs to the broader category of melanocytic lesions; that broader category also includes malignant processes such as melanoma. Pigment production, cellular lineage and malignant behavior are different properties.[ref]
Common Moles, Dysplastic Nevi, and Risk of Melanoma by the National Cancer Institute. What is a common mole? and distinction between noncancerous moles and melanoma
The biology is particularly interesting because a growth-promoting molecular alteration can occur without establishing malignancy. Pamela M. Pollock and colleagues analyzed BRAF mutations in microdissected melanocytic samples. They found the substitution designated V599E in the original 2003 paper in 63 of 77 nevi, as well as in melanoma samples. Their interpretation was that pathway activation alone was insufficient for melanoma formation.[ref]
High frequency of BRAF mutations in nevi by Pamela M. Pollock and others. Abstract, microdissected specimens, mutation counts and sufficiency interpretation
The observed nevus fraction is in that study's material. It is not a probability that an individual nevus will later become malignant: the counted event was a mutation in sampled tissue, not a future outcome followed over time. Estimating progression would require a different study design and a defined observation interval. The original mutation label is retained here as historical source terminology rather than silently equating residue-numbering conventions.
A skin biopsy supplies tissue architecture as well as cells for molecular analysis. Clinicopathological correlation relates that specimen to the lesion's observed location, extent and history, while diagnostic reproducibility asks how consistently its findings are classified. A molecular result can add evidence without replacing either the sampled architecture or the clinical question. This separation explains why detecting an alteration in a signaling gene is not by itself a complete diagnosis of malignant behavior.
Melanoma Created 2026-10-31 Updated 2026-11-05
A cancer arising from melanocytes. Pigment production can vary, so a melanoma need not be visibly dark, and a dark lesion is not automatically melanoma.
Melanotic tumour 2026-10-31
An historically appropriate classification distinguishes the hard, soft, gelatinous, pigmented and epithelial malignant growths, together with recurrent and destructive growths whose place in “cancer” was disputed. Modern classification instead distinguishes tumours by cellular lineage and biological behaviour.
The quotation marks around “Malignant” matter. In 1867 the clinical grouping did not have a single settled boundary in histology. Infiltration, destructive growth, return after removal, spread to distant sites and progressive constitutional illness were warning features; hardness or rapid growth alone was not a sufficient definition. A contemporary review of an 1866 textbook explicitly disputed confused descriptions of hard and soft cancer, illustrating that this was already a live diagnostic controversy.[ref]
Review of Demonstrations of Microscopic Anatomy (1866 book). Discussion under “tumours”, contrasting scirrhus with encephaloid, melanotic and colloid growths and rejecting an indiscriminate use of “cancer”
A useful period classification, without pretending that every contemporary author drew the same boundaries, is:
- Scirrhous carcinoma, or hard cancer. Abundant firm fibrous supporting tissue makes a hard, often contracted growth, classically in the breast. Retraction and fixation reflect invasion and contraction of that supporting tissue. “Hard” describes the gross appearance; it is not a separate modern cellular lineage.
- Encephaloid cancer, or medullary/soft cancer. The name refers to soft, brain-like tissue, often richly cellular and prone to rapid growth, breakdown and haemorrhage. The historical label could include more than one modern diagnosis; it does not mean a tumour of the brain.
- Colloid cancer. A gelatinous appearance associated with abundant mucin. Some such lesions would now be classified as mucinous carcinomas; appearance alone cannot retrospectively determine their modern identity.
- Melanotic tumour. Dark pigment supplied a gross category. Many malignant examples belong to modern melanoma, arising from melanocytes, but pigmentation is neither necessary nor sufficient for melanoma. Pigmented examples could also be treated as varieties within other period categories.
- Epithelioma, or epithelial cancer. A growth exhibiting epithelial structure, especially at skin and mucous membrane surfaces. Many examples correspond to squamous cell carcinoma. A locally destructive rodent ulcer, now generally basal cell carcinoma, was sometimes separated because distant spread was unusual.
- Recurrent fibroid tumour and related “fibroplastic” or other sarcomas. These could return repeatedly and invade locally despite differing from the period's typical cancer. They were sometimes called semi-malignant. A reported 1866 recurrent fibroid tumour developed distant deposits after apparently successful local treatment: a vivid reason that a purely local category could fail.[ref]St George's Hospital Reports (1866). Case of recurrent fibroid tumour of the thigh, subsequent constitutional disease and post-mortem deposits; terminology is the report's historical terminology
Those are overlapping historical descriptive groups, not six mutually exclusive modern diagnoses. Nor does every growth historically called “sarcoma” meet the modern definition of sarcoma.
The modern organising principle asks what cells are malignant. Carcinoma arises from epithelium; sarcoma arises in bone or soft tissue; melanoma arises from melanocytes; lymphoma and leukaemia concern blood-forming or immune cells. Other families include central nervous system and germ cell tumours. A solid lump is not essential for cancer. Within a family, histology, immunohistochemistry and appropriate molecular diagnostics refine the diagnosis. Tumour grade describes features of aggressiveness, whereas tumour stage describes extent of disease.[ref]
This also corrects the old inference that recurrence must reflect a mysterious constitutional deposit: local residual disease and metastasis are distinct mechanisms, and an apparently circumscribed growth may already have disseminated.